Monitor for future disclosures on royalty income, commercial performance of the enhanced OneTest for Longevity, and any announcement of the East Asian commercialization agreement. The partnership may improve platform differentiation in the longevity analytics market, but near-term financial impact is uncertain.
Price Chart
Executive Summary
20/20 Biolabs (AIDX) announced an exclusive U.S. technology license and access agreement with ROKIT Healthcare to integrate ROKIT’s chronic kidney disease (CKD) prediction algorithm into 20/20’s Longevity Platform. ROKIT will reimburse one-third of agreed sales and marketing expenses in exchange for a running royalty on net sales, with potential for expanded commercialization in Korea and other East Asian markets.
Key Facts
- 20/20 Biolabs entered into an exclusive U.S. technology license agreement with ROKIT Healthcare.
- ROKIT’s CKD prediction algorithm will be integrated into 20/20’s OneTest for Longevity platform.
- ROKIT will reimburse 20/20 for one-third of mutually agreed sales and marketing expenses.
- ROKIT will receive a running royalty on net sales of the combined product.
- Potential future agreement for ROKIT to commercialize 20/20’s platform in Korea and other East Asian markets is under discussion.
- No financial terms such as deal value, revenue projections, or royalty rates were disclosed.
Financial Impact
Unknown — no specific financial figures disclosed; potential future revenue from royalties and shared marketing funding.
Risk Factors
- No guaranteed revenue — financial benefit depends on future product adoption and sales.
- Dependence on ROKIT’s commercial execution, particularly in international markets.
- Forward-looking statements dominate the release; actual outcomes may differ materially.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261237 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | DEFA14A | $0.2507 | awaiting T+5 | — | $0.2400 (−4.27%) |
Oct 21, 2026 4d ago | DEF 14A | $0.2507 | awaiting T+5 | — | $0.2400 (−4.27%) |
Aug 17, 2026 9w ago | 8-K | $0.5200 $0.5282 | ▲ +1.58% | ▲ +1.78% | $0.2400 (−53.85%) |
Aug 17, 2026 10w ago | Press Release | $0.5503 $0.5182 | ▼ −5.83% | ▼ −4.64% | $0.2400 (−56.39%) |
Aug 5, 2026 11w ago | 8-K | $0.4413 $0.4610 | ▲ +4.46% | ▲ +4.11% | $0.2400 (−45.62%) |
Jul 1, 2026 16w ago | 8-K | $0.6095 $0.5851 | ▼ −4.00% | ▼ −4.26% | $0.2400 (−60.62%) |
Jun 23, 2026 17w ago | DEFA14A | $0.5669 $0.6095 | ▼ −7.51% | ▼ −5.81% | $0.2400 (+57.66%) |
May 26, 2026 21w ago | 8-K | $0.9700 $0.8400 | ▼ −13.40% | ▼ −13.87% | $0.2400 (−75.26%) |
May 20, 2026 22w ago | 8-K | $1.21 $0.9500 | ▲ +21.49% | ▲ +23.09% | $0.2400 (+80.17%) |
May 20, 2026 22w ago | Press Release | $1.21 $0.9500 | ▲ +21.49% | ▲ +23.09% | $0.2400 (+80.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers